Arthur H. Amron
Director · NEPHROS INC
- 2024
- Sep 16, 2026
- 9
Summary
Latest filing:
Arthur H. Amron is Director of NEPHROS INC (NEPH). 9 SEC Form 4 filings on record going back to 2024, most recently on 16 September 2026. Most recent open-market trade: bought $7K of TUSK on 15 June 2026. Lifetime open-market purchases: $35K.
Recent transactions
14The latest 14 SEC Form 4 transactions reported by Arthur H. Amron.
Trading pattern
InsiderAlpha's records for Arthur H. Amron go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. The typical open-market purchase is $7K (5 buys totaling $35K). The largest single buy on record is $10K of TUSK in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same sector
No other insider has filed at Arthur H. Amron's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Herriot Tabuteau - $97.80M in AXSM purchases and sales in the last 12 months
- Paul A. Mahon - $93.78M in UTHR purchases and sales in the last 12 months
- SUVRETTA CAPITAL MANAGEMENT, LLC - $90.98M in MANE purchases and sales in the last 12 months
- Ugur Sahin - $84.23M in BNTX purchases and sales in the last 12 months
- Mark T. Bertolini - $82.60M in OSCR purchases and sales in the last 12 months
- Frank Torti - $82.04M in ROIV purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Arthur H. Amron?
Arthur H. Amron is a corporate insider, tracked as Director of NEPHROS INC (NEPH). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Arthur H. Amron submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Arthur H. Amron been buying or selling stock?
Recorded transactions: 5 open-market purchases ($35K) and 0 open-market sales across all tracked filings.